1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Chronic Refractory Cough (CRC) - Epidemiology Forecast to 2030

Chronic Refractory Cough (CRC) - Epidemiology Forecast to 2030

  • February 2021
  • 80 pages
  • ID: 6028057
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Chronic Refractory Cough (CRC) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Refractory Cough (CRC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Chronic Refractory Cough (CRC) Understanding
Chronic refractory cough (CRC) is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialties: Pulmonology, Allergy and Immunology, Digestive Health and Otorhinolaryngology. Patients with chronic cough experience impaired quality of life and interruption of activities of daily living. It can result in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough, chronic idiopathic cough, unexplained chronic cough, and cough hypersensitivity syndrome. CRC is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritated cough which may be localized to the laryngeal region. Chronic coughs last more than 8 weeks and can be caused by gastroesophageal reflux disease (GERD), postnasal drip from sinus infections or allergies, or chronic lung conditions, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and interstitial lung diseases.

CRC is caused due to the recurrent occurrence of chronic cough. However, the signs and symptoms of chronic cough are similar to that of CRC. Persistent or chronic cough is one of the first and important symptoms and may signify respiratory involvement. Other pulmonary symptoms and signs include wheezing, stridor, dyspnea, hoarseness or aphonia, and tenderness over the laryngotracheal cartilage. Key symptoms include a dry irritating cough localized around the laryngeal region. Certain factors like smoking, allergies, chronic lung diseases, obesity and others can increase the risk of CRC.

Chronic refractory cough often occurs after a viral infection and multiple factors contribute to CRC which is divided according to the conditions affecting the upper and lower respiratory tracts. Often the etiology can be multifactorial with more than one pathology present. Chronic cough causes social isolation, anxiety, and depression. Laryngopharyngeal reflux (LPR) is a common cause of CRC and may be present without symptoms of classic gastroesophageal reflux disease (GORD), including heartburn (silent reflux). There is an increasing awareness of neural hypersensitivity (laryngeal cough hypersensitivity syndrome) as a contributor to chronic cough and its pathophysiology has featured in common with neuropathic pain syndromes. Obstructive sleep apnoea syndrome (OSAS) has also recently been identified as an independent risk factor for chronic cough and a risk factor for LPR/GORD recalcitrant to medical therapy. ACE inhibitors are another common cause of CRC, which can occur spontaneously even after many years on this medication without previous problems. Sometimes, despite extensive investigation and trials of empirical therapy, the cause for cough remains unexplained and in such instances is termed an idiopathic or unexplained chronic cough.

Chronic Refractory Cough (CRC) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Chronic Cough, Gender-specific Prevalent Population of Chronic Cough, Prevalent Population of Chronic Refractory Cough (CRC), Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) and Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) in Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.
Chronic Refractory Cough (CRC) Detailed Epidemiology Segmentation
• The total prevalent population of Chronic Cough in the 7 major markets was estimated to be 84,854,266 in 2020.
• The prevalent population of CRC in the 7 major markets was estimated to be 17,600,264 in 2020.
• The total diagnosed prevalent population of CRC in the 7 major markets was estimated to be 10,560,159 in 2020. In case of CRC patients in the United States, the diagnosed prevalent cases were 4,802,273 in 2020.
• The diagnosed prevalent population of CRC in the 7 MM is expected to increase at a CAGR of 0.48% during the forecast period 2021–2030.
• In the EU5 countries, the prevalent population of Chronic Cough was maximum in France with 8,799,771 cases followed by the United Kingdom with 8,682,007 cases in 2020. While, Spain accounted for the lowest diagnosed prevalent population of the indication with 5,708,813 cases in 2020.
• As per the analysis, Japan had 683,935 diagnosed prevalent cases of CRC in 2020.
• In the United States, the total prevalent cases of Chronic Cough comprised of 10,805,114 males and 29,213,828 females in 2020.
• The total number of diagnosed prevalent cases of CRC in IPF patients was 106,801 in the United States, in 2020.

Scope of the Report
• The report covers the descriptive overview of Chronic Refractory Cough (CRC), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Refractory Cough (CRC).
• The report provides the segmentation of the disease epidemiology for the 7MM by Prevalent Population of Chronic Cough, Gender-specific Prevalent Population of Chronic Cough, Prevalent Population of Chronic Refractory Cough (CRC), Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) and Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) in Idiopathic Pulmonary Fibrosis (IPF) patients.

Report Highlights
• Ten Year Forecast of Chronic Refractory Cough (CRC)
• 7MM Coverage
• Total Diagnosed Prevalent Population of Chronic Refractory Cough (CRC)
• Delvelnsight has analysed prevalent population of Chronic cough and CRC in the 7MM for the study period of 2018–2030.
• Diagnosed prevalence of CRC was also assessed, which suggests that the cases of CRC will increase during the forecast period of 2021–2030.
• In addition, gener-specific prevalence of Chronic Cough was also assessed. As per the analysis, CRC is more prevalent in females than in males.
• The report also encompasses another major segment, i.e., Diagnosed Prevalent Population of CRC in IPF patients, wherein the number of IPF patients suffering from CRC was calculated.
Analyst Comments
• Various epidemiological studies on chronic cough are available in the US and European countries through which its prevalence has been estimated. However, the prevalent population for CRC has been derived from the prevalent patient pool of chronic cough in the 7 MM.
• It is important to note that even though there is a shortage of detailed epidemiological studies on chronic cough and CRC in Japan, however, The analyst has referred to certain regional studies to understand the basis of the disease occurrence in the country.
• Futhermore, IPF can be termed as a major contributor of CRC patient pool, therefore, the prevalence of CRC in IPF patients has also been estimated in this report.

Key Questions Answered
• What is the disease risk, burden and unmet needs of Chronic Refractory Cough (CRC)?
• What is the historical Chronic Refractory Cough (CRC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Chronic Refractory Cough (CRC) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Refractory Cough (CRC)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Refractory Cough (CRC) during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy
The Chronic Refractory Cough (CRC) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Chronic Refractory Cough (CRC) market.
• Quantify patient share distribution in the 7MM for Chronic Refractory Cough (CRC).
• The Chronic Refractory Cough (CRC) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Chronic Refractory Cough (CRC) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2018–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on